Overview

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to evaluate different dosages of risperidone ISM, a new long-acting injectable form.
Phase:
Phase 1
Details
Lead Sponsor:
Rovi Pharmaceuticals Laboratories
Treatments:
Risperidone